ALEXANDER MAYWEG

Alexander Mayweg stands as a distinguished Managing Director at Versant Ventures, a leading healthcare venture capital firm. Based in Basel, Switzerland, he plays a pivotal role in Versant's European operations, spearheading new company generation and strategic investments across the vibrant European life sciences landscape. His expertise is particularly focused on identifying and nurturing groundbreaking biotech companies, with a strong emphasis on drug discovery and development. Alexander Mayweg's contributions are instrumental in translating cutting-edge scientific research into viable therapeutic solutions.

At Versant Ventures, Alexander Mayweg is known for his hands-on approach to company creation. He works closely with scientific founders to build innovative startups from the ground up, leveraging his extensive industry knowledge and network. His investment interests span a wide range of therapeutic areas, always with an eye towards novel mechanisms of action and significant unmet medical needs. This strategic focus ensures that Versant Ventures supports companies poised to make a substantial impact on patient care.

Prior to joining Versant Ventures in 2012, Alexander Mayweg built an impressive career marked by significant leadership roles in both pharmaceutical partnering and venture capital. He served as the Head of Pharma Partnering Europe at Roche, where he was responsible for strategic alliances and collaborations across the continent. Before this, he led the Roche Venture Fund, gaining invaluable experience in identifying and investing in promising early-stage life science companies. His earlier career included key business development and licensing positions at Actelion and Novartis, further solidifying his expertise in the commercialization of pharmaceutical innovations.

Alexander Mayweg's academic background is equally robust, holding a Ph.D. in chemistry from the ETH Zurich. He further honed his scientific acumen through postdoctoral research at Stanford University, providing him with a deep understanding of the scientific principles underpinning the biotech ventures he now champions. This blend of scientific rigor and business acumen makes him a formidable force in the venture capital world.

Throughout his tenure, Alexander Mayweg has been involved in numerous successful ventures that have gone on to achieve significant milestones. Notable companies he has helped build or invest in include Black Diamond Therapeutics (NASDAQ: BDTX), Monte Rosa Therapeutics (NASDAQ: MRTA), and Inception Therapeutics, which was successfully acquired by Roche. Other impactful companies in his portfolio include Amira Pharmaceuticals (acquired by BMS), Quanta Therapeutics, Bright Peak Therapeutics, T-CURX, Point Biopharma, Metris Therapeutics, and Stroma Therapeutics. His track record underscores his ability to identify and cultivate companies with high growth potential and transformative technologies. Alexander Mayweg continues to be a driving force in shaping the future of European biotech, consistently seeking out opportunities to back the next generation of life-changing therapies.